Pfizer (PFE) Canada said Monday its Ixifi drug will be available in Canada starting April 1.
Ixifi, or infliximab for injection, is a biosimilar to Remicade, the company said.
The drug was approved by Health Canada in December 2021 for all eligible indications of the reference product, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis, the company said.
Price: 25.98, Change: +0.26, Percent Change: +1.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.